Schwannoma - dismech

◆

Subtypes

5

anatomic clinical

Vestibular Schwannoma (Acoustic Neuroma)

The most common schwannoma; arises on the vestibulocochlear (eighth cranial) nerve in the internal auditory canal/cerebellopontine angle. Usually unilateral and sporadic, but characteristically bilateral in NF2-related schwannomatosis. Presents with hearing loss, tinnitus, and imbalance.

Show evidence (1 reference)

PMID:20301380 SUPPORT Human Clinical

"NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."

GeneReviews defines bilateral vestibular schwannomas as the hallmark of NF2-related disease.

histologic

Cellular Schwannoma

A histologic variant composed predominantly of compact, hypercellular Antoni A tissue with few or no Verocay bodies and occasional mitoses. It is benign but can be mistaken for malignant peripheral nerve sheath tumor; it retains S-100/SOX10 positivity and an encapsulated/lobular pattern.

Plexiform Schwannoma

A multinodular ("plexiform") growth pattern of schwannoma involving multiple fascicles, often cutaneous or subcutaneous. Benign, but its multinodular architecture can raise concern for plexiform neurofibroma or malignancy.

Melanotic (Psammomatous) Schwannoma

A rare pigmented variant in which neoplastic Schwann cells contain melanin; the psammomatous subtype contains psammoma bodies and is associated with the Carney complex (PRKAR1A). Unlike most schwannomas, melanotic schwannoma carries a non-trivial risk of malignant behavior.

genetic context

SMARCB1/LZTR1-Related Schwannoma (Schwannomatosis)

Schwannomas arising in non-NF2 schwannomatosis caused by germline pathogenic variants in SMARCB1 or LZTR1, predisposing to multiple non-intradermal peripheral and spinal schwannomas. SMARCB1 loss underlies most epithelioid schwannomas and carries a higher malignancy risk than LZTR1-related disease.

Show evidence (2 references)

PMID:29517885 SUPPORT Human Clinical

"LZTR1- and SMARCB1-related schwannomatosis are characterized by a predisposition to develop multiple non-intradermal schwannomas."

GeneReviews defines SMARCB1/LZTR1-related schwannomatosis by multiple non-intradermal schwannomas.

PMID:29517885 SUPPORT Human Clinical

"Malignancy remains a risk especially in individuals with SMARCB1-related schwannomatosis."

GeneReviews notes the elevated malignancy risk in SMARCB1-related schwannomatosis.

⚙

Pathophysiology

6

Biallelic NF2 Merlin Inactivation

The initiating event in most schwannomas is biallelic inactivation of the NF2 tumor suppressor gene and loss of its product merlin/schwannomin, a 4.1/ERM-family cytoskeleton-to-membrane linker with cell-type-specific growth-inhibiting activity. NF2 deficiency is associated with a narrow tumor spectrum dominated by schwannomas and meningiomas.

Schwann cell CL:0002573

NF2 hgnc:7773

peripheral nervous system UBERON:0000010

Downstream

Loss of Contact-Dependent Growth Inhibition Merlin loss abolishes contact-dependent inhibition of Schwann-cell proliferation.

Show evidence (2 references)

PMID:19029950 SUPPORT In Vitro

"The NF2 gene product, merlin/schwannomin, is a cytoskeleton organizer with unique growth-inhibiting activity in specific cell types."

Establishes merlin/schwannomin as the NF2 product with cell-type-specific growth-inhibitory activity.

PMID:19029950 SUPPORT In Vitro

"A narrow spectrum of tumors is associated with NF2 deficiency, mainly schwannomas and meningiomas, suggesting cell-specific mechanisms of growth control."

Supports the narrow NF2-deficiency tumor spectrum dominated by schwannomas.

Loss of Contact-Dependent Growth Inhibition

Merlin normally restrains growth by controlling contact-dependent inhibition of proliferation. At cell-to-cell contact merlin limits the delivery and membrane accumulation of growth factor receptors. Loss of merlin removes this brake, so Schwann cells continue proliferating despite confluence — the permissive state for schwannoma formation.

Schwann cell CL:0002573

contact inhibition GO:0060242 ↓ DECREASED negative regulation of cell population proliferation GO:0008285 ↓ DECREASED

Downstream

Receptor Tyrosine Kinase and RAS-MAPK Activation Loss of contact inhibition is accompanied by accumulation of ErbB/RTK receptors and mitogenic signaling.

YAP/TAZ-TEAD Transcriptional Activation Merlin loss de-represses the Hippo effectors YAP/TAZ.

Show evidence (2 references)

PMID:21481793 SUPPORT In Vitro

"The Merlin/NF2 tumor suppressor restrains cell growth and tumorigenesis by controlling contact-dependent inhibition of proliferation."

Directly supports merlin's control of contact-dependent inhibition of proliferation.

PMID:19029950 SUPPORT In Vitro

"We found that merlin regulates contact inhibition of proliferation by limiting the delivery of several growth factor receptors at the plasma membrane of primary SCs."

Shows merlin enforces contact inhibition by limiting growth-factor-receptor delivery in Schwann cells.

Receptor Tyrosine Kinase and RAS-MAPK Activation

Upon cell-to-cell contact, merlin downregulates membrane levels of ErbB2 and ErbB3, inhibiting downstream AKT (protein kinase B) and MAPK signaling. Loss of merlin causes accumulation of ErbB2/3, IGF1R, and PDGFR in Schwann cells and human schwannomas, driving mitogenic signaling. The merlin-angiomotin complex additionally restrains Rac1 and the Ras-MAPK pathway.

Schwann cell CL:0002573

ERBB signaling pathway GO:0038127 ↑ INCREASED

Downstream

mTORC1 Activation RTK/PI3K signaling converges on mTORC1 in merlin-deficient tumors.

Schwann-Cell Proliferation and Benign Tumor Formation Sustained mitogenic signaling drives Schwann-cell proliferation.

Show evidence (3 references)

PMID:19029950 SUPPORT In Vitro

"upon cell-to-cell contact, merlin downregulates the membrane levels of ErbB2 and ErbB3, thus inhibiting the activity of the downstream mitogenic signaling pathways protein kinase B and mitogen-activated protein kinase."

Supports merlin's suppression of ErbB2/3-driven AKT/MAPK mitogenic signaling, lost in schwannoma.

PMID:19029950 SUPPORT In Vitro

"We also observed accumulation of growth factor receptors such as ErbB2 and 3, insulin-like growth factor 1 receptor and platelet-derived growth factor receptor in peripheral nerves of Nf2-mutant mice and in human NF2 schwannomas"

Documents RTK accumulation in human NF2 schwannomas and Nf2-mutant nerves.

PMID:21481793 SUPPORT In Vitro

"Depletion of Angiomotin in Nf2(-/-) Schwann cells attenuates the Ras-MAPK signaling pathway, impedes cellular proliferation in vitro and tumorigenesis in vivo."

Links the merlin-angiomotin axis to Ras-MAPK signaling and proliferation in Nf2-null Schwann cells.

YAP/TAZ-TEAD Transcriptional Activation

Merlin signals through the Hippo pathway; merlin loss releases the transcriptional coactivators YAP and TAZ, which translocate to the nucleus and drive TEAD-dependent proliferative transcription. NF2-null schwannoma cells depend on YAP/TAZ-TEAD activity, and genetic or pharmacologic inhibition of TEAD blocks (and can regress) schwannoma growth.

Schwann cell CL:0002573

hippo signaling GO:0035329 ↓ DECREASED positive regulation of Schwann cell proliferation GO:0010625 ↑ INCREASED

Downstream

Schwann-Cell Proliferation and Benign Tumor Formation YAP/TAZ-TEAD output drives the proliferative program of schwannoma cells.

Show evidence (4 references)

PMID:18953429 SUPPORT In Vitro

"merlin controls cell proliferation and apoptosis by signaling through the Hippo pathway to inhibit the function of the transcriptional coactivator Yorkie."

Establishes the merlin-Hippo-YAP (Yorkie) axis controlling proliferation; mechanism shared by NF2-null tumors.

PMID:18953429 PARTIAL In Vitro

"merlin loss in both meningioma cell lines and primary tumors resulted in increased YAP expression and nuclear localization."

Demonstrates merlin loss increases nuclear YAP; shown in NF2-null meningioma, the paralogous NF2-driven tumor (PARTIAL because the cells are meningioma, not schwannoma).

PMID:36148553 SUPPORT In Vitro

"Schwannoma tumours typically arise on the eighth cranial nerve and are mostly caused by loss of the tumour suppressor Merlin (NF2)."

Confirms merlin/NF2 loss as the predominant schwannoma driver.

+ 1 more reference

mTORC1 Activation

Merlin-deficient tumors show activation of the mTORC1 signaling pathway, considered a key driver of tumor growth in NF2-deficient tumors and a rationale for mTOR inhibitor therapy, although clinical mTORC1 inhibition has been largely cytostatic rather than tumor-shrinking.

Schwann cell CL:0002573

TOR signaling GO:0031929 ↑ INCREASED

Show evidence (1 reference)

PMID:24311643 SUPPORT Human Clinical

"Activation of the mammalian target of rapamycin (mTOR) signaling pathway is thought to be a key driver of tumor growth in Merlin (NF2)-deficient tumors."

Supports mTOR pathway activation as a proposed driver in merlin-deficient tumors.

Schwann-Cell Proliferation and Benign Tumor Formation

Convergent loss of growth restraint and activation of YAP/TAZ-TEAD, RTK/MAPK, and mTORC1 signaling drive clonal proliferation of neoplastic Schwann cells, producing an encapsulated, slow-growing, benign nerve-sheath tumor (Antoni A palisading Verocay bodies and myxoid Antoni B areas). Malignant transformation is rare.

Schwann cell CL:0002573

Schwann cell proliferation GO:0014010 ↑ INCREASED

Show evidence (1 reference)

PMID:36148553 SUPPORT In Vitro

"we have examined the role of the Hippo signalling pathway in driving tumour cell growth."

Frames Hippo-driven proliferation as the engine of schwannoma tumor growth.

✶

Histopathology

3

Antoni A Spindle-Cell Areas with Verocay Bodies VERY_FREQUENT

Compact, hypercellular Antoni A tissue of spindled Schwann cells with nuclear palisading forming Verocay bodies is a characteristic schwannoma pattern, set against looser, myxoid Antoni B areas.

Show evidence (1 reference)

PMID:28368924 SUPPORT Human Clinical

"Some tumors showed foci resembling conventional schwannoma (spindled morphology, 29; Antoni B foci or Verocay bodies, 8; hyalinized thick-walled vessels, 16)."

Documents the conventional schwannoma features (spindled morphology, Antoni B foci, Verocay bodies) used diagnostically.

S-100 and SOX10 Positivity VERY_FREQUENT

Schwann-cell origin is confirmed by diffuse S-100 protein positivity and consistent SOX10 nuclear positivity, distinguishing schwannoma from non-neural mimics.

Show evidence (1 reference)

PMID:28368924 SUPPORT Human Clinical

"All tumors showed diffuse positivity for S-100 protein and consistent positivity for SOX10 (50/50)"

Supports diffuse S-100/SOX10 positivity as a defining schwannoma immunophenotype.

SMARCB1/INI1 Loss in Epithelioid Schwannoma FREQUENT

The epithelioid variant of schwannoma frequently shows loss of SMARCB1/INI1 nuclear expression, linking it mechanistically to SMARCB1-related schwannomatosis.

Show evidence (1 reference)

PMID:28368924 SUPPORT Human Clinical

"Loss of SMARCB1/INI1 expression is seen in 42% of tumors."

Quantifies SMARCB1/INI1 loss in epithelioid schwannoma.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Ear 3

Hearing Impairment Hearing impairment HP:0000365

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:20301380 SUPPORT Human Clinical

"NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."

GeneReviews lists hearing loss among the core vestibular-schwannoma symptoms.

Tinnitus Tinnitus HP:0000360

Show evidence (1 reference)

PMID:20301380 SUPPORT Human Clinical

"NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."

GeneReviews lists tinnitus among the core vestibular-schwannoma symptoms.

Balance Dysfunction Vertigo HP:0002321

Show evidence (1 reference)

PMID:20301380 SUPPORT Human Clinical

"NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."

GeneReviews lists balance dysfunction among the core vestibular-schwannoma symptoms.

Neoplasm 1

Pain or Asymptomatic Mass Neoplasm HP:0002664

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"The most common presenting feature is localized or diffuse pain or asymptomatic mass."

Supports pain or an asymptomatic mass as the typical schwannomatosis presentation.

Other 1

Schwannoma (Peripheral Nerve Sheath Tumor) Schwannoma HP:0100008

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Schwannomas most often affect peripheral nerves and spinal nerves."

Supports schwannomas of peripheral and spinal nerves as the core manifestation.

🧬

Genetic Associations

3

NF2 biallelic inactivation (Biallelic NF2 inactivation (germline plus somatic, or two somatic hits) is the central driver of sporadic schwannoma and NF2-related schwannomatosis.)

Gene: NF2 hgnc:7773 relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:36148553 SUPPORT In Vitro

"Schwannoma tumours typically arise on the eighth cranial nerve and are mostly caused by loss of the tumour suppressor Merlin (NF2)."

Supports NF2/merlin loss as the predominant cause of schwannoma.

SMARCB1 germline pathogenic variant (Germline SMARCB1 variants cause SMARCB1-related schwannomatosis with multiple non-intradermal schwannomas; SMARCB1/INI1 loss characterizes epithelioid schwannoma. SMARCB1-related disease carries elevated malignancy and meningioma risk.)

Gene: SMARCB1 hgnc:11103 relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."

Supports germline SMARCB1 variants as causative of SMARCB1-related schwannomatosis.

LZTR1 germline pathogenic variant (Germline LZTR1 variants cause LZTR1-related schwannomatosis with multiple non-intradermal schwannomas, including a risk of unilateral vestibular schwannoma.)

Gene: LZTR1 hgnc:6742 relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."

Supports germline LZTR1 variants as causative of LZTR1-related schwannomatosis.

💊

Medical Actions

5

Microsurgical Resection

Action: surgical procedure MAXO:0000004

Surgical removal is the mainstay for symptomatic or growing schwannomas; surgery on vestibular schwannomas carries risk to the eighth and adjacent cranial nerves. Surgery is indicated for schwannomas causing uncontrolled localized pain or a neurologic deficit.

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"surgery for schwannomas associated with uncontrolled localized pain or a neurologic deficit"

GeneReviews supports surgical resection for symptomatic schwannomas.

Stereotactic Radiosurgery

Action: stereotactic radiosurgery MAXO:0009088

Stereotactic radiosurgery (e.g., Gamma Knife) is a non-surgical option for small to medium vestibular schwannomas. In hereditary schwannomatosis, radiation can increase the risk of malignant transformation and should be used cautiously.

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Radiation can increase the risk for malignant transformation and should be"

GeneReviews drug/agent-safety warning that radiation can promote malignant transformation in schwannomatosis.

Bevacizumab

Action: Pharmacotherapy NCIT:C15986

Agent: bevacizumab NCIT:C2039

Bevacizumab, an anti-VEGF monoclonal antibody, can reduce tumor volume and improve hearing in NF2-related progressive vestibular schwannomas, targeting VEGF-driven tumor vasculature.

Target Phenotypes: Hearing impairment HP:0000365

Show evidence (2 references)

PMID:19587327 SUPPORT Human Clinical

"After bevacizumab treatment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up."

Demonstrates tumor shrinkage with bevacizumab in NF2-related vestibular schwannoma.

PMID:19587327 SUPPORT Human Clinical

"of the remaining seven patients, four had a hearing response, two had stable hearing, and one had progressive hearing loss."

Documents hearing improvement with bevacizumab, supporting its use against VS-related hearing loss.

mTOR Inhibition (Everolimus)

Action: Pharmacotherapy NCIT:C15986

Agent: everolimus CHEBI:68478

Everolimus, an oral mTORC1 inhibitor, was evaluated in progressive NF2-related vestibular schwannoma based on mTOR activation in merlin-deficient tumors; a phase II study showed no objective tumor or hearing responses, so it is not an effective monotherapy.

Show evidence (1 reference)

PMID:24311643 REFUTE Human Clinical

"Everolimus is ineffective for the treatment of progressive VS in NF2 patients."

Phase II evidence that everolimus monotherapy is ineffective for progressive vestibular schwannoma.

Active Surveillance

Action: active surveillance Ontology label: surveillance for malignancies MAXO:0001492

Many small, asymptomatic schwannomas are monitored with serial imaging and audiometry. GeneReviews recommends periodic neurologic examination, pain assessment, and brain/spine MRI surveillance in schwannomatosis.

Show evidence (1 reference)

PMID:29517885 SUPPORT Human Clinical

"Annual neurologic examination and pain assessment; brain and spine MRI or whole-body MRI every two to three years beginning at age 12 years"

GeneReviews supports surveillance imaging and neurologic monitoring in schwannomatosis.

{ }

Source YAML

click to show

name: Schwannoma
creation_date: '2026-06-08T00:00:00Z'
category: Neoplastic
categories:
- Benign Neoplasm
- Peripheral Nerve Sheath Tumor
synonyms:
- neurilemmoma
- neurinoma
- benign schwannoma
- schwannoma (WHO grade I)
disease_term:
  preferred_term: schwannoma
  term:
    id: MONDO:0002546
    label: schwannoma
description: >-
  Schwannoma is a benign, usually encapsulated, slow-growing peripheral
  nerve-sheath tumor composed almost entirely of neoplastic Schwann cells.
  The central molecular event is biallelic inactivation of the NF2 tumor
  suppressor gene and loss of its product merlin/schwannomin, which removes
  contact-dependent growth inhibition and de-represses downstream proliferative
  signaling — Hippo/YAP-TAZ-TEAD transcriptional output, receptor tyrosine
  kinase (ErbB2/3, IGF1R, PDGFR) accumulation with RAS-MAPK and PI3K-AKT
  activation, and mTORC1 signaling. Most schwannomas are sporadic and solitary,
  but they also arise in NF2-related schwannomatosis (characteristically
  bilateral vestibular schwannomas, meningiomas, and ependymomas) and in
  SMARCB1- or LZTR1-related schwannomatosis. Histologically schwannomas show
  compact, spindle-cell Antoni A areas with nuclear-palisading Verocay bodies,
  looser myxoid Antoni B areas, diffuse S-100/SOX10 positivity, and an
  encapsulated growth pattern. Recognized histologic variants include cellular,
  plexiform, melanotic/psammomatous, and epithelioid (SMARCB1/INI1-deficient)
  schwannoma. Malignant transformation is rare.
parents:
- nerve sheath neoplasm
- benign peripheral nerve sheath tumor
references:
- reference: PMID:20301380
  title: "NF2-Related Schwannomatosis."
  tags:
  - GeneReviews
- reference: PMID:29517885
  title: "LZTR1- and SMARCB1-Related Schwannomatosis."
  tags:
  - GeneReviews
has_subtypes:
- name: Vestibular Schwannoma
  display_name: Vestibular Schwannoma (Acoustic Neuroma)
  classification: anatomic_clinical
  description: >-
    The most common schwannoma; arises on the vestibulocochlear (eighth cranial)
    nerve in the internal auditory canal/cerebellopontine angle. Usually
    unilateral and sporadic, but characteristically bilateral in NF2-related
    schwannomatosis. Presents with hearing loss, tinnitus, and imbalance.
  evidence:
  - reference: PMID:20301380
    reference_title: "NF2-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."
    explanation: GeneReviews defines bilateral vestibular schwannomas as the hallmark of NF2-related disease.
- name: Cellular Schwannoma
  classification: histologic
  description: >-
    A histologic variant composed predominantly of compact, hypercellular
    Antoni A tissue with few or no Verocay bodies and occasional mitoses. It is
    benign but can be mistaken for malignant peripheral nerve sheath tumor; it
    retains S-100/SOX10 positivity and an encapsulated/lobular pattern.
- name: Plexiform Schwannoma
  classification: histologic
  description: >-
    A multinodular ("plexiform") growth pattern of schwannoma involving multiple
    fascicles, often cutaneous or subcutaneous. Benign, but its multinodular
    architecture can raise concern for plexiform neurofibroma or malignancy.
- name: Melanotic/Psammomatous Schwannoma
  display_name: Melanotic (Psammomatous) Schwannoma
  classification: histologic
  description: >-
    A rare pigmented variant in which neoplastic Schwann cells contain melanin;
    the psammomatous subtype contains psammoma bodies and is associated with the
    Carney complex (PRKAR1A). Unlike most schwannomas, melanotic schwannoma
    carries a non-trivial risk of malignant behavior.
- name: SMARCB1/LZTR1-Related
  display_name: SMARCB1/LZTR1-Related Schwannoma (Schwannomatosis)
  classification: genetic_context
  description: >-
    Schwannomas arising in non-NF2 schwannomatosis caused by germline pathogenic
    variants in SMARCB1 or LZTR1, predisposing to multiple non-intradermal
    peripheral and spinal schwannomas. SMARCB1 loss underlies most epithelioid
    schwannomas and carries a higher malignancy risk than LZTR1-related disease.
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LZTR1- and SMARCB1-related schwannomatosis are characterized by a predisposition to develop multiple non-intradermal schwannomas."
    explanation: GeneReviews defines SMARCB1/LZTR1-related schwannomatosis by multiple non-intradermal schwannomas.
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignancy remains a risk especially in individuals with SMARCB1-related schwannomatosis."
    explanation: GeneReviews notes the elevated malignancy risk in SMARCB1-related schwannomatosis.
pathophysiology:
- name: Biallelic NF2 Merlin Inactivation
  description: >-
    The initiating event in most schwannomas is biallelic inactivation of the
    NF2 tumor suppressor gene and loss of its product merlin/schwannomin, a
    4.1/ERM-family cytoskeleton-to-membrane linker with cell-type-specific
    growth-inhibiting activity. NF2 deficiency is associated with a narrow
    tumor spectrum dominated by schwannomas and meningiomas.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  evidence:
  - reference: PMID:19029950
    reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The NF2 gene product, merlin/schwannomin, is a cytoskeleton organizer with unique growth-inhibiting activity in specific cell types."
    explanation: Establishes merlin/schwannomin as the NF2 product with cell-type-specific growth-inhibitory activity.
  - reference: PMID:19029950
    reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "A narrow spectrum of tumors is associated with NF2 deficiency, mainly schwannomas and meningiomas, suggesting cell-specific mechanisms of growth control."
    explanation: Supports the narrow NF2-deficiency tumor spectrum dominated by schwannomas.
  downstream:
  - target: Loss of Contact-Dependent Growth Inhibition
    description: Merlin loss abolishes contact-dependent inhibition of Schwann-cell proliferation.
- name: Loss of Contact-Dependent Growth Inhibition
  description: >-
    Merlin normally restrains growth by controlling contact-dependent inhibition
    of proliferation. At cell-to-cell contact merlin limits the delivery and
    membrane accumulation of growth factor receptors. Loss of merlin removes
    this brake, so Schwann cells continue proliferating despite confluence —
    the permissive state for schwannoma formation.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: contact inhibition
    modifier: DECREASED
    term:
      id: GO:0060242
      label: contact inhibition
  - preferred_term: negative regulation of cell population proliferation
    modifier: DECREASED
    term:
      id: GO:0008285
      label: negative regulation of cell population proliferation
  evidence:
  - reference: PMID:21481793
    reference_title: A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The Merlin/NF2 tumor suppressor restrains cell growth and tumorigenesis by controlling contact-dependent inhibition of proliferation."
    explanation: Directly supports merlin's control of contact-dependent inhibition of proliferation.
  - reference: PMID:19029950
    reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We found that merlin regulates contact inhibition of proliferation by limiting the delivery of several growth factor receptors at the plasma membrane of primary SCs."
    explanation: Shows merlin enforces contact inhibition by limiting growth-factor-receptor delivery in Schwann cells.
  downstream:
  - target: Receptor Tyrosine Kinase and RAS-MAPK Activation
    description: Loss of contact inhibition is accompanied by accumulation of ErbB/RTK receptors and mitogenic signaling.
  - target: YAP/TAZ-TEAD Transcriptional Activation
    description: Merlin loss de-represses the Hippo effectors YAP/TAZ.
- name: Receptor Tyrosine Kinase and RAS-MAPK Activation
  description: >-
    Upon cell-to-cell contact, merlin downregulates membrane levels of ErbB2 and
    ErbB3, inhibiting downstream AKT (protein kinase B) and MAPK signaling. Loss
    of merlin causes accumulation of ErbB2/3, IGF1R, and PDGFR in Schwann cells
    and human schwannomas, driving mitogenic signaling. The merlin-angiomotin
    complex additionally restrains Rac1 and the Ras-MAPK pathway.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: ERBB signaling pathway
    modifier: INCREASED
    term:
      id: GO:0038127
      label: ERBB signaling pathway
  evidence:
  - reference: PMID:19029950
    reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "upon cell-to-cell contact, merlin downregulates the membrane levels of ErbB2 and ErbB3, thus inhibiting the activity of the downstream mitogenic signaling pathways protein kinase B and mitogen-activated protein kinase."
    explanation: Supports merlin's suppression of ErbB2/3-driven AKT/MAPK mitogenic signaling, lost in schwannoma.
  - reference: PMID:19029950
    reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We also observed accumulation of growth factor receptors such as ErbB2 and 3, insulin-like growth factor 1 receptor and platelet-derived growth factor receptor in peripheral nerves of Nf2-mutant mice and in human NF2 schwannomas"
    explanation: Documents RTK accumulation in human NF2 schwannomas and Nf2-mutant nerves.
  - reference: PMID:21481793
    reference_title: A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Depletion of Angiomotin in Nf2(-/-) Schwann cells attenuates the Ras-MAPK signaling pathway, impedes cellular proliferation in vitro and tumorigenesis in vivo."
    explanation: Links the merlin-angiomotin axis to Ras-MAPK signaling and proliferation in Nf2-null Schwann cells.
  downstream:
  - target: mTORC1 Activation
    description: RTK/PI3K signaling converges on mTORC1 in merlin-deficient tumors.
  - target: Schwann-Cell Proliferation and Benign Tumor Formation
    description: Sustained mitogenic signaling drives Schwann-cell proliferation.
- name: YAP/TAZ-TEAD Transcriptional Activation
  description: >-
    Merlin signals through the Hippo pathway; merlin loss releases the
    transcriptional coactivators YAP and TAZ, which translocate to the nucleus
    and drive TEAD-dependent proliferative transcription. NF2-null schwannoma
    cells depend on YAP/TAZ-TEAD activity, and genetic or pharmacologic
    inhibition of TEAD blocks (and can regress) schwannoma growth.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: hippo signaling
    modifier: DECREASED
    term:
      id: GO:0035329
      label: hippo signaling
  - preferred_term: positive regulation of Schwann cell proliferation
    modifier: INCREASED
    term:
      id: GO:0010625
      label: positive regulation of Schwann cell proliferation
  evidence:
  - reference: PMID:18953429
    reference_title: The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "merlin controls cell proliferation and apoptosis by signaling through the Hippo pathway to inhibit the function of the transcriptional coactivator Yorkie."
    explanation: Establishes the merlin-Hippo-YAP (Yorkie) axis controlling proliferation; mechanism shared by NF2-null tumors.
  - reference: PMID:18953429
    reference_title: The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "merlin loss in both meningioma cell lines and primary tumors resulted in increased YAP expression and nuclear localization."
    explanation: Demonstrates merlin loss increases nuclear YAP; shown in NF2-null meningioma, the paralogous NF2-driven tumor (PARTIAL because the cells are meningioma, not schwannoma).
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Schwannoma tumours typically arise on the eighth cranial nerve and are mostly caused by loss of the tumour suppressor Merlin (NF2)."
    explanation: Confirms merlin/NF2 loss as the predominant schwannoma driver.
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
    explanation: In vivo mouse-model evidence that YAP/TAZ-TEAD activity is required for schwannoma growth.
  downstream:
  - target: Schwann-Cell Proliferation and Benign Tumor Formation
    description: YAP/TAZ-TEAD output drives the proliferative program of schwannoma cells.
- name: mTORC1 Activation
  description: >-
    Merlin-deficient tumors show activation of the mTORC1 signaling pathway,
    considered a key driver of tumor growth in NF2-deficient tumors and a
    rationale for mTOR inhibitor therapy, although clinical mTORC1 inhibition has
    been largely cytostatic rather than tumor-shrinking.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: TOR signaling
    modifier: INCREASED
    term:
      id: GO:0031929
      label: TOR signaling
  evidence:
  - reference: PMID:24311643
    reference_title: Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Activation of the mammalian target of rapamycin (mTOR) signaling pathway is thought to be a key driver of tumor growth in Merlin (NF2)-deficient tumors."
    explanation: Supports mTOR pathway activation as a proposed driver in merlin-deficient tumors.
- name: Schwann-Cell Proliferation and Benign Tumor Formation
  description: >-
    Convergent loss of growth restraint and activation of YAP/TAZ-TEAD, RTK/MAPK,
    and mTORC1 signaling drive clonal proliferation of neoplastic Schwann cells,
    producing an encapsulated, slow-growing, benign nerve-sheath tumor (Antoni A
    palisading Verocay bodies and myxoid Antoni B areas). Malignant
    transformation is rare.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: Schwann cell proliferation
    modifier: INCREASED
    term:
      id: GO:0014010
      label: Schwann cell proliferation
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we have examined the role of the Hippo signalling pathway in driving tumour cell growth."
    explanation: Frames Hippo-driven proliferation as the engine of schwannoma tumor growth.
histopathology:
- name: Antoni A Spindle-Cell Areas with Verocay Bodies
  finding_term:
    preferred_term: Antoni A pattern with nuclear-palisading Verocay bodies
    term:
      id: NCIT:C53643
      label: Spindle Cell Pattern
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Compact, hypercellular Antoni A tissue of spindled Schwann cells with nuclear
    palisading forming Verocay bodies is a characteristic schwannoma pattern, set
    against looser, myxoid Antoni B areas.
  evidence:
  - reference: PMID:28368924
    reference_title: "SMARCB1/INI1 Loss in Epithelioid Schwannoma: A Clinicopathologic and Immunohistochemical Study of 65 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some tumors showed foci resembling conventional schwannoma (spindled morphology, 29; Antoni B foci or Verocay bodies, 8; hyalinized thick-walled vessels, 16)."
    explanation: Documents the conventional schwannoma features (spindled morphology, Antoni B foci, Verocay bodies) used diagnostically.
- name: S-100 and SOX10 Positivity
  finding_term:
    preferred_term: Diffuse S-100 and SOX10 immunopositivity
    term:
      id: NCIT:C35867
      label: Morphologic Finding
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Schwann-cell origin is confirmed by diffuse S-100 protein positivity and
    consistent SOX10 nuclear positivity, distinguishing schwannoma from
    non-neural mimics.
  evidence:
  - reference: PMID:28368924
    reference_title: "SMARCB1/INI1 Loss in Epithelioid Schwannoma: A Clinicopathologic and Immunohistochemical Study of 65 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All tumors showed diffuse positivity for S-100 protein and consistent positivity for SOX10 (50/50)"
    explanation: Supports diffuse S-100/SOX10 positivity as a defining schwannoma immunophenotype.
- name: SMARCB1/INI1 Loss in Epithelioid Schwannoma
  finding_term:
    preferred_term: Loss of SMARCB1/INI1 nuclear expression
    term:
      id: NCIT:C35867
      label: Morphologic Finding
  frequency: FREQUENT
  description: >-
    The epithelioid variant of schwannoma frequently shows loss of SMARCB1/INI1
    nuclear expression, linking it mechanistically to SMARCB1-related
    schwannomatosis.
  evidence:
  - reference: PMID:28368924
    reference_title: "SMARCB1/INI1 Loss in Epithelioid Schwannoma: A Clinicopathologic and Immunohistochemical Study of 65 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Loss of SMARCB1/INI1 expression is seen in 42% of tumors."
    explanation: Quantifies SMARCB1/INI1 loss in epithelioid schwannoma.
phenotypes:
- name: Schwannoma (Peripheral Nerve Sheath Tumor)
  description: >-
    The defining manifestation is one or more benign Schwann-cell tumors of
    cranial, spinal, or peripheral nerves.
  phenotype_term:
    preferred_term: Schwannoma
    term:
      id: HP:0100008
      label: Schwannoma
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Schwannomas most often affect peripheral nerves and spinal nerves."
    explanation: Supports schwannomas of peripheral and spinal nerves as the core manifestation.
- name: Hearing Impairment
  description: >-
    Sensorineural hearing loss results from vestibular schwannoma compressing or
    infiltrating the cochlear nerve; it is a hallmark of NF2-related disease.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301380
    reference_title: "NF2-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."
    explanation: GeneReviews lists hearing loss among the core vestibular-schwannoma symptoms.
- name: Tinnitus
  description: >-
    Tinnitus is a common symptom of vestibular schwannoma reflecting eighth-nerve
    involvement.
  phenotype_term:
    preferred_term: Tinnitus
    term:
      id: HP:0000360
      label: Tinnitus
  evidence:
  - reference: PMID:20301380
    reference_title: "NF2-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."
    explanation: GeneReviews lists tinnitus among the core vestibular-schwannoma symptoms.
- name: Balance Dysfunction
  description: >-
    Imbalance, disequilibrium, and vertigo arise from vestibular-nerve
    involvement by vestibular schwannoma.
  phenotype_term:
    preferred_term: Vertigo or disequilibrium
    term:
      id: HP:0002321
      label: Vertigo
  evidence:
  - reference: PMID:20301380
    reference_title: "NF2-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."
    explanation: GeneReviews lists balance dysfunction among the core vestibular-schwannoma symptoms.
- name: Pain or Asymptomatic Mass
  description: >-
    In non-vestibular and schwannomatosis-associated schwannomas, the most common
    presentation is localized or diffuse pain or an asymptomatic palpable mass.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common presenting feature is localized or diffuse pain or asymptomatic mass."
    explanation: Supports pain or an asymptomatic mass as the typical schwannomatosis presentation.
genetic:
- name: NF2 biallelic inactivation
  gene_term:
    preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  association: >-
    Biallelic NF2 inactivation (germline plus somatic, or two somatic hits) is
    the central driver of sporadic schwannoma and NF2-related schwannomatosis.
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Schwannoma tumours typically arise on the eighth cranial nerve and are mostly caused by loss of the tumour suppressor Merlin (NF2)."
    explanation: Supports NF2/merlin loss as the predominant cause of schwannoma.
- name: SMARCB1 germline pathogenic variant
  gene_term:
    preferred_term: SMARCB1
    term:
      id: hgnc:11103
      label: SMARCB1
  association: >-
    Germline SMARCB1 variants cause SMARCB1-related schwannomatosis with multiple
    non-intradermal schwannomas; SMARCB1/INI1 loss characterizes epithelioid
    schwannoma. SMARCB1-related disease carries elevated malignancy and
    meningioma risk.
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."
    explanation: Supports germline SMARCB1 variants as causative of SMARCB1-related schwannomatosis.
- name: LZTR1 germline pathogenic variant
  gene_term:
    preferred_term: LZTR1
    term:
      id: hgnc:6742
      label: LZTR1
  association: >-
    Germline LZTR1 variants cause LZTR1-related schwannomatosis with multiple
    non-intradermal schwannomas, including a risk of unilateral vestibular
    schwannoma.
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing."
    explanation: Supports germline LZTR1 variants as causative of LZTR1-related schwannomatosis.
treatments:
- name: Microsurgical Resection
  description: >-
    Surgical removal is the mainstay for symptomatic or growing schwannomas;
    surgery on vestibular schwannomas carries risk to the eighth and adjacent
    cranial nerves. Surgery is indicated for schwannomas causing uncontrolled
    localized pain or a neurologic deficit.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "surgery for schwannomas associated with uncontrolled localized pain or a neurologic deficit"
    explanation: GeneReviews supports surgical resection for symptomatic schwannomas.
- name: Stereotactic Radiosurgery
  description: >-
    Stereotactic radiosurgery (e.g., Gamma Knife) is a non-surgical option for
    small to medium vestibular schwannomas. In hereditary schwannomatosis,
    radiation can increase the risk of malignant transformation and should be
    used cautiously.
  treatment_term:
    preferred_term: stereotactic radiosurgery
    term:
      id: MAXO:0009088
      label: stereotactic radiosurgery
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Radiation can increase the risk for malignant transformation and should be"
    explanation: GeneReviews drug/agent-safety warning that radiation can promote malignant transformation in schwannomatosis.
- name: Bevacizumab
  description: >-
    Bevacizumab, an anti-VEGF monoclonal antibody, can reduce tumor volume and
    improve hearing in NF2-related progressive vestibular schwannomas, targeting
    VEGF-driven tumor vasculature.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bevacizumab
      term:
        id: NCIT:C2039
        label: Bevacizumab
  target_phenotypes:
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:19587327
    reference_title: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After bevacizumab treatment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up."
    explanation: Demonstrates tumor shrinkage with bevacizumab in NF2-related vestibular schwannoma.
  - reference: PMID:19587327
    reference_title: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "of the remaining seven patients, four had a hearing response, two had stable hearing, and one had progressive hearing loss."
    explanation: Documents hearing improvement with bevacizumab, supporting its use against VS-related hearing loss.
- name: mTOR Inhibition (Everolimus)
  description: >-
    Everolimus, an oral mTORC1 inhibitor, was evaluated in progressive NF2-related
    vestibular schwannoma based on mTOR activation in merlin-deficient tumors;
    a phase II study showed no objective tumor or hearing responses, so it is not
    an effective monotherapy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: everolimus
      term:
        id: CHEBI:68478
        label: everolimus
  evidence:
  - reference: PMID:24311643
    reference_title: Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Everolimus is ineffective for the treatment of progressive VS in NF2 patients."
    explanation: Phase II evidence that everolimus monotherapy is ineffective for progressive vestibular schwannoma.
- name: Active Surveillance
  description: >-
    Many small, asymptomatic schwannomas are monitored with serial imaging and
    audiometry. GeneReviews recommends periodic neurologic examination, pain
    assessment, and brain/spine MRI surveillance in schwannomatosis.
  treatment_term:
    preferred_term: active surveillance
    term:
      id: MAXO:0001492
      label: surveillance for malignancies
  evidence:
  - reference: PMID:29517885
    reference_title: "LZTR1- and SMARCB1-Related Schwannomatosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Annual neurologic examination and pain assessment; brain and spine MRI or whole-body MRI every two to three years beginning at age 12 years"
    explanation: GeneReviews supports surveillance imaging and neurologic monitoring in schwannomatosis.

📚

References & Deep Research

References

2

PMID:20301380

NF2-Related Schwannomatosis.

No top-level findings curated for this source.

PMID:29517885

LZTR1- and SMARCB1-Related Schwannomatosis.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 29 citations 2026-06-08T12:24:26.415813

1. Disease Information

1.1 Definition and overview

Schwannoma: a benign peripheral nerve sheath tumor derived from myelinating Schwann cells; can occur in cranial, spinal, and peripheral nerves. (tsuchiya2025currentmolecularunderstanding, abstract evidence) (otaner2026vestibularschwannomagenetic pages 1-2)
Vestibular schwannoma (VS) (synonym: acoustic neuroma): a benign Schwann-cell tumor of the vestibulocochlear nerve (CN VIII); clinically important for hearing/balance deficits. (otaner2026vestibularschwannomagenetic pages 1-2, screnci2024bevacizumabforvestibular pages 1-2)

1.2 Key identifiers and ontology mappings (available in current corpus)

MONDO
Schwannomatosis: MONDO_0008075 (OpenTargets mapping) (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis)
NF2-related schwannomatosis: MONDO_0007039 (OpenTargets mapping) (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis)
EFO
Schwannoma: EFO_0000693 (OpenTargets mapping) (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis)

Not retrieved in the current evidence set (therefore not asserted here): MeSH ID, ICD-10/ICD-11 codes, Orphanet/OMIM identifiers for schwannoma/VS.

1.3 Common synonyms / alternative names

Vestibular schwannoma = acoustic neuroma (explicit in systematic review background) (screnci2024bevacizumabforvestibular pages 1-2)
“Neurofibromatosis type 2” renamed to NF2-related schwannomatosis per international consensus (see below) (perrino2025updateoncancer pages 3-4, rai2025classificationofschwannomas pages 1-2, tamura2024historicaldevelopmentof pages 1-3)

1.4 Evidence-source type

The consensus terminology/diagnostic criteria and clinical outcomes summarized below are derived from aggregated disease-level resources (systematic reviews, consensus updates, surveillance recommendations) plus clinical cohort studies and ClinicalTrials.gov registrations (chiranth2023asystematicreview pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, douwes2024bevacizumabtreatmentfor pages 9-11, NCT04374305 chunk 1).

2. Etiology

2.1 Primary causal factors

2.1.1 Sporadic schwannoma / VS

VS is predominantly sporadic: review-level summary states ~90% are sporadic (otaner2026vestibularschwannomagenetic pages 1-2).
Molecular driver in VS: NF2 loss/merlin deficiency is described as central to pathogenesis, with downstream dysregulation of Hippo/YAP-TAZ, PI3K/AKT/mTOR, VEGF, MAPK, and adhesion pathways (otaner2026vestibularschwannomagenetic pages 1-2).

2.1.2 Schwannomatosis syndromes (germline predisposition)

A key 2022–2025 development is gene-based classification of “schwannomatoses” as cancer predisposition syndromes caused by germline pathogenic variants: * Perrino et al. (2025) abstract: “Schwannomatoses (SWN) are distinct cancer predisposition syndromes caused by germline pathogenic variants in the genes NF2, SMARCB1, or LZTR1.” (Feb 2025) (perrino2025updateoncancer pages 3-4) * Perrino et al. (2025) abstract: “Neurofibromatosis type 2 was recently renamed as NF2-related SWN …” (perrino2025updateoncancer pages 3-4)

OpenTargets also highlights NF2, SMARCB1, and LZTR1 as top disease-associated targets for schwannoma/schwannomatosis, consistent with genetic causality in these syndromes (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis).

2.2 Risk factors

Genetic risk (major): germline pathogenic variants in NF2, SMARCB1, or LZTR1 for schwannomatosis syndromes (perrino2025updateoncancer pages 3-4, tamura2024historicaldevelopmentof pages 3-4, OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis).
Mosaicism is an important risk/diagnostic factor in NF2-related schwannomatosis; consensus criteria define mosaic status using low variant allele fraction (VAF) in blood/saliva or shared variants across anatomically unrelated tumors (tamura2024historicaldevelopmentof pages 3-4).

Environmental/lifestyle risk factors: not established in the retrieved evidence for schwannoma causation. A 2023 review on hearing loss and VS notes attention to “environmental factors” that could contribute to hearing loss progression, but does not provide validated causal environmental risk factors for schwannoma itself in the retrieved excerpt (otaner2026vestibularschwannomagenetic pages 1-2).

2.3 Protective factors / gene–environment interactions

Not identified in the retrieved evidence set.

3. Phenotypes (clinical features)

3.1 Core phenotype spectrum (with suggested HPO terms)

Vestibular schwannoma (sporadic or NF2-related)

Sensorineural hearing loss (often progressive) due to VS (chiranth2023asystematicreview pages 1-2, screnci2024bevacizumabforvestibular pages 1-2).
Suggested HPO: HP:0000407 Sensorineural hearing impairment
Balance/vestibular dysfunction (balance issues emphasized as common presenting feature) (screnci2024bevacizumabforvestibular pages 1-2).
Suggested HPO: HP:0001751 Vertigo / HP:0002321 Abnormality of balance
Cranial nerve compression / brainstem compression (noted as a clinical issue in VS context) (lu2024enhancedtumorcontrol pages 1-4).
Suggested HPO: HP:0002366 Brainstem compression

Schwannomatosis syndromes (NF2-, SMARCB1-, LZTR1-related)

Multiple cranial, spinal, and peripheral schwannomas (hallmark) (perrino2025updateoncancer pages 3-4).
Suggested HPO: HP:0009589 Bilateral vestibular schwannoma (NF2-related) and/or HP:0009733 Schwannoma
Meningiomas and less commonly ependymoma in NF2-related schwannomatosis (perrino2025updateoncancer pages 3-4).
Suggested HPO: HP:0002858 Meningioma, HP:0100826 Ependymoma
Chronic pain is emphasized for schwannomatosis (“hallmark” symptom in non-NF2 schwannomatosis literature; treatment resistant) (perrino2025updateoncancer pages 5-7).
Suggested HPO: HP:0012531 Pain (consider more specific pain terms by location)

3.2 Age of onset / progression

VS median diagnosis age (sporadic) reported as ~60 years; NF2-associated VS often presents earlier (18–24 years) (otaner2026vestibularschwannomagenetic pages 1-2).
NF2-related schwannomatosis is described as dominantly inherited; birth incidence reported as ~1:25,000–33,000 (systematic review) (chiranth2023asystematicreview pages 1-2) and as ~1 in 61,000 (preclinical paper background statement) (lu2024enhancedtumorcontrol pages 1-4).

3.3 Quality-of-life impact

Hearing loss and balance impairment are major morbidity drivers for VS/NF2 (screnci2024bevacizumabforvestibular pages 1-2).
In a phase II axitinib study, a validated NF2-related quality-of-life measure (NFTI-QOL) was used and remained stable or improved during treatment (clinical trial report abstract evidence) (douwes2024bevacizumabtreatmentfor pages 9-11).

4. Genetic/Molecular Information

4.1 Causal genes and molecular classification (2022 consensus framework)

2022 consensus updates changed both nomenclature and diagnostic criteria: * “Schwannomatosis” used as an umbrella term for disorders that predispose to schwannomas, and each type is classified by the causative gene; “NF2 is now termed NF2-related schwannomatosis.” (Tamura 2024) (tamura2024historicaldevelopmentof pages 1-3) * Gene-based syndromes highlighted in 2025 surveillance perspective: NF2-, SMARCB1-, LZTR1-related schwannomatosis (perrino2025updateoncancer pages 3-4).

4.2 Pathogenic variants / variant origin

NF2-related schwannomatosis: NF2 pathogenic variants may be detectable in blood in ~66–90% (Tamura 2024 excerpt) (tamura2024historicaldevelopmentof pages 3-4).
Mosaic NF2-related schwannomatosis: defined by VAF clearly <50% in blood/saliva or shared pathogenic variant across anatomically unrelated tumors but absent from unaffected tissue (tamura2024historicaldevelopmentof pages 3-4).

4.3 Pathways and mechanisms (current understanding; 2023–2024 emphasis)

Review synthesis for VS: merlin deficiency leads to dysregulation of Hippo/YAP-TAZ, PI3K/AKT/mTOR, VEGF, MAPK, and adhesion pathways (otaner2026vestibularschwannomagenetic pages 1-2).
Mechanistic review of NF2 (2024, NPJ Precision Oncology): merlin is an ERM-family scaffold; NF2 loss dysregulates Hippo kinase cascades converging on LATS1/2, enabling YAP-driven transcription; therapeutic concepts include targeting Hippo/YAP, mTOR, FAK, and others (xu2024nf2anunderestimated pages 2-3).

4.3.1 Hippo–YAP/TAZ–TEAD as a therapeutic vulnerability (primary evidence)

A key 2023 advance is direct preclinical demonstration that inhibiting TEAD activity can regress schwannoma: * Laraba et al. (Brain, Sep 2023) used human primary schwannoma cells and mouse schwannoma models and found that genetic ablation of YAP/TAZ or TEAD palmitoylation inhibitors can block and regress schwannoma growth, supporting Hippo pathway targeting (laraba2023inhibitionofyaptazdriven pages 1-2, laraba2023inhibitionofyaptazdriven pages 2-3).

Visual evidence: the in vivo regression effect with TEAD auto-palmitoylation inhibitors is shown in a central figure with tumor-volume reductions and increased apoptosis (cropped figure region) (laraba2023inhibitionofyaptazdriven media d8f8c3e0).

4.4 Epigenetic / multi-omics profiling

VS review notes epigenetic alterations (DNA methylation, chromatin remodeling, non-coding RNAs) and SOX10 dysfunction shaping tumor behavior (otaner2026vestibularschwannomagenetic pages 1-2).

Not retrievable here: specific methylation signatures, transcriptomic/proteomic markers, or single-cell datasets are referenced in some reviews but not captured with extractable quantitative details in the current evidence excerpts.

Suggested GO / CL terms (for knowledge-base annotation)

Key biological processes (GO):
Hippo signaling (e.g., GO:0035329 hippo signaling)
Regulation of cell proliferation (GO:0042127)
Angiogenesis / VEGF signaling (GO:0001525 angiogenesis)
Cell types (CL):
Schwann cell (CL:0000218)

5. Environmental Information

No validated causal environmental exposures for schwannoma were identified in the retrieved evidence set. Environmental factors are discussed in the context of hearing loss broadly, but without definitive etiologic linkage to schwannoma occurrence in the excerpts available (otaner2026vestibularschwannomagenetic pages 1-2).

6. Mechanism / Pathophysiology (causal chain)

6.1 Example causal chain: NF2 loss → pathway dysregulation → tumor growth and hearing loss

Initial trigger: NF2 inactivation (germline + second hit in syndromic disease; somatic loss in sporadic VS). (otaner2026vestibularschwannomagenetic pages 1-2, tamura2024historicaldevelopmentof pages 3-4)
Upstream molecular consequence: loss of merlin’s tumor-suppressive scaffolding and regulation of contact inhibition and Hippo kinase activation. (xu2024nf2anunderestimated pages 2-3)
Downstream transcriptional programs: increased YAP/TAZ–TEAD activity; additional dysregulation in PI3K/AKT/mTOR, MAPK, VEGF pathways (review synthesis). (otaner2026vestibularschwannomagenetic pages 1-2)
Cellular phenotype: Schwann-cell proliferation and tumor maintenance; vascular and inflammatory changes may contribute to hearing loss beyond pure nerve compression. (otaner2026vestibularschwannomagenetic pages 1-2)

6.2 Hearing loss mechanisms in VS

VS-associated hearing loss described as multifactorial, involving tumor-secreted factors, inflammation, vascular changes, and inner ear damage, alongside nerve compression (otaner2026vestibularschwannomagenetic pages 1-2).

7. Anatomical Structures Affected

7.1 Organ and system level (with UBERON suggestions)

Peripheral nervous system and cranial nerves; specifically the vestibulocochlear nerve in VS (screnci2024bevacizumabforvestibular pages 1-2).
Suggested UBERON: vestibulocochlear nerve (UBERON:0001643)
NF2-related schwannomatosis also involves intracranial tumors including meningiomas and occasionally ependymoma (perrino2025updateoncancer pages 3-4).
Suggested UBERON: meninges (UBERON:0000966); spinal cord (UBERON:0002240)

7.2 Tissue/cell level

Tumor cell-of-origin: myelinating Schwann cells (otaner2026vestibularschwannomagenetic pages 1-2).
CL: Schwann cell (CL:0000218)

7.3 Subcellular level

Not specifically defined in retrieved evidence excerpts.

8. Temporal Development

NF2-related schwannomatosis typically manifests with bilateral VS and other tumors over time; mosaic phenotypes complicate clinical onset patterns (tamura2024historicaldevelopmentof pages 3-4).
VS can be managed with observation vs active therapy depending on growth and symptom trajectory (general management options noted in review) (otaner2026vestibularschwannomagenetic pages 1-2).

9. Inheritance and Population

9.1 Inheritance

NF2-related schwannomatosis: autosomal dominant cancer predisposition syndrome (chiranth2023asystematicreview pages 1-2, lu2024enhancedtumorcontrol pages 1-4).

9.2 Epidemiology statistics (from retrieved sources)

NF2 birth incidence in systematic reviews: ~1:25,000–33,000 (chiranth2023asystematicreview pages 1-2, screnci2024bevacizumabforvestibular pages 1-2).
Preclinical background statement: NF2-related schwannomatosis incidence ~1 in 61,000 (lu2024enhancedtumorcontrol pages 1-4).

Note: Incidence/prevalence for all schwannomas (sporadic) were not retrieved in the current evidence set.

10. Diagnostics

10.1 2022 international diagnostic criteria highlights (NF2-related schwannomatosis)

Tamura et al. (2024) summarizes consensus criteria: * Diagnosis can be made by (1) bilateral vestibular schwannomas, (2) an identical NF2 pathogenic variant in ≥2 anatomically distinct NF2-related tumors, or (3) combinations of major/minor criteria (tamura2024historicaldevelopmentof pages 3-4). * Mosaic NF2: “clearly less than 50%” pathogenic VAF in blood/saliva, or shared pathogenic variant across ≥2 anatomically unrelated tumors but absent from unaffected tissue (tamura2024historicaldevelopmentof pages 3-4).

10.2 Diagnostic testing modalities (from available evidence)

Imaging: MRI-based management and surveillance are foundational (explicitly referenced across reviews, though detailed MRI criteria are not extractable in current excerpts) (otaner2026vestibularschwannomagenetic pages 1-2, tamura2024historicaldevelopmentof pages 3-4).
Genetic testing: consensus emphasizes integrating blood/saliva and tumor testing to resolve gene subtype and mosaicism (rai2025classificationofschwannomas pages 1-2, tamura2024historicaldevelopmentof pages 3-4).

10.3 Differential diagnosis

Not systematically extractable from current excerpts (e.g., neurofibroma vs schwannoma, meningioma, MPNST). A 2025 review notes hybrid neurofibroma/schwannoma can be diagnostically confusing (retrieved but not evidence-extracted here).

11. Outcome / Prognosis

11.1 Treatment response metrics as prognostic indicators

Systemic therapy outcomes in NF2-related VS are commonly assessed using volumetric radiographic response (>20% decrease) and hearing response metrics (WRS, PTA), as used in systematic reviews and cohort studies (chiranth2023asystematicreview pages 1-2, douwes2024bevacizumabtreatmentfor pages 2-4).

11.2 Progression after stopping therapy

In a single-center cohort, post-treatment radiologic surveillance showed 55% progression after stopping bevacizumab (with median post-treatment follow-up 19.3 months), and symptom worsening was frequent after discontinuation (douwes2024bevacizumabtreatmentfor pages 8-9, douwes2024bevacizumabtreatmentfor pages 9-11).

12. Treatment (current applications and real-world implementations)

12.1 Standard local management

VS management options include observation, microsurgery, and stereotactic radiosurgery, as summarized in a recent narrative review (otaner2026vestibularschwannomagenetic pages 1-2).

12.2 Systemic therapies (NF2-related VS): bevacizumab and beyond

Bevacizumab (anti-VEGF monoclonal antibody) is consistently the systemic therapy with the strongest clinical signal in NF2-related VS, though generally off-label and supported mainly by single-arm/retrospective evidence (otaner2026vestibularschwannomagenetic pages 1-2, chiranth2023asystematicreview pages 1-2, douwes2024bevacizumabtreatmentfor pages 9-11).

The table below compiles key quantitative efficacy/toxicity statistics from 2023–2024 reviews and a 2024 real-world cohort.

Source	Population	N	Bevacizumab dose/schedule	Radiographic response definition and rates	Hearing response definition and rates	Key adverse events and rates	Notes
Chiranth et al., 2023, Neuro-Oncology Advances, DOI: https://doi.org/10.1093/noajnl/vdad099	NF2-related schwannomatosis with vestibular schwannoma; pooled systematic review of targeted therapy studies	200 across 10 bevacizumab studies (16 total studies tested 6 drugs)	Review-level summary; notes that lower-dose bevacizumab may retain efficacy with less toxicity	REiNS volumetric criteria: radiographic response (RR) = >20% tumor-volume decrease; progression = >20% increase. Pooled bevacizumab RR 38% (95% CI 31–45%); bevacizumab had highest efficacy among targeted agents reviewed	Pooled hearing response (HR) 45% (95% CI 36–54%)	Common toxicities: hypertension and menorrhagia	Comparator agents in review: lapatinib RR 6%, HR 31%; VEGFR vaccine RR 29%, HR 40%. Authors conclude bevacizumab showed the highest efficacy, but further trials of other agents/combination therapy are needed (chiranth2023asystematicreview pages 1-2)
Screnci et al., 2024, Journal of Clinical Medicine, DOI: https://doi.org/10.3390/jcm13237488	Neurofibromatosis type 2 / NF2-related vestibular schwannoma; systematic review	176 across 9 studies	Not consistently reported in pooled excerpt	Partial tumor volume reduction defined as ≥20%: 40%; disease stabilization 50%; progression 10%	Hearing improvement 36%; hearing stabilization 46%; hearing deterioration 18%	Severe adverse effects in 13% (including hypertension and thromboembolic events); 18% reported no side effects	Tumor regrowth observed in some patients after treatment discontinuation, supporting need for long-term monitoring (screnci2024bevacizumabforvestibular pages 1-2)
Douwes et al., 2024, Cancers, DOI: https://doi.org/10.3390/cancers16081479	Single-center NF2-related schwannomatosis cohort treated for target vestibular schwannoma	17 patients; radiology evaluable in 16; hearing evaluable in 15 target ears; post-treatment symptom surveillance in 11; post-treatment radiology in 12	Median 7.5 mg/kg IV every 3 weeks (range 5.6–7.5; interval range 3.0–4.4 weeks); planned regimen 7.5 mg/kg q3wk for at least 6 months; median duration 7.1 months (range 2.1–23.9)	Definition: improved = ≥20% decrease in extrameatal volume; stable = between −20% and +20%; worsened = ≥20% increase. On treatment: regression 31% (5/16), stable 69% (11/16), no ≥20% progression reported. Median extrameatal volume 1.24 cm^3 to 1.15 cm^3. Pre-treatment growth 43% overall (15% annually) vs −12% overall (−13% annually) during treatment. Post-treatment surveillance: 9% regression, 36% stable, 55% progression	Definition: improved = ≥10% WRS increase; worsened = ≥10% WRS decrease; if WRS remained 100%, ≥10 dB PTA change considered significant. On treatment: 40% improved, 53% stable, 7% worsened in target ears (6/15, 8/15, 1/15); reported as hearing preservation 93%. Median WRS 74% to 82%; median PTA 57 dB to 61 dB. After discontinuation (n=11), 82% stable and 18% hearing loss	94% had ≥1 adverse event; 50 total AEs: grade 1 62%, grade 2 34%, grade 3 4%, no grade 4/5. Hypertension 82% (grade 3 in 12%; 36% of hypertensive patients required antihypertensives), fatigue 29%, proteinuria 6%. Treatment discontinuation due to AEs in 29%	Indications: progressive hearing loss 59%, other NF2 symptoms 35%, tumor size 6%. Symptoms improved in 41%, stable in 47%, worsened in 12% during treatment; summarized as clinical symptom improvement/preservation in 88%. Reasons for stopping included radiologic stability/regression and/or hearing benefit, AEs (29%), response failure (6%), patient preference (6%). After stopping (median surveillance 29.2 months), 27% remained stable and 73% worsened symptomatically; no further symptom improvement. Four patients were retreated with mixed results; two maintenance-regimen patients remained stable (douwes2024bevacizumabtreatmentfor pages 5-8, douwes2024bevacizumabtreatmentfor pages 9-11, douwes2024bevacizumabtreatmentfor pages 4-5, douwes2024bevacizumabtreatmentfor pages 8-9, douwes2024bevacizumabtreatmentfor pages 2-4)

Table: This table compiles the main quantitative bevacizumab outcomes for NF2-related vestibular schwannoma from a 2023 systematic review, a 2024 systematic review, and a 2024 single-center cohort. It is useful for comparing pooled efficacy, toxicity, and post-discontinuation patterns across evidence sources.

Real-world implementation example (single-center, 2013–2023): * Douwes et al. (Cancers, Apr 2024) used 7.5 mg/kg IV every 3 weeks (median duration 7.1 months) and reported hearing preservation 93%, with 31% tumor regression and 69% stable disease; adverse events were common (hypertension 82%; discontinuation due to AEs 29%) (douwes2024bevacizumabtreatmentfor pages 9-11, douwes2024bevacizumabtreatmentfor pages 4-5).

12.3 Emerging targeted and immunologic strategies (2023–2024)

Hippo pathway targeting (TEAD palmitoylation inhibitors): preclinical evidence supports regression of NF2-null schwannoma using TEAD inhibitors (Laraba et al., Brain 2023) (laraba2023inhibitionofyaptazdriven pages 1-2, laraba2023inhibitionofyaptazdriven media d8f8c3e0).
Combination immunotherapy + anti-VEGF (preclinical): combined anti-PD1 + anti-VEGF improved tumor control and preserved hearing in immune-competent VS models, suggesting a rationale for combination approaches (bioRxiv Dec 2024) (lu2024enhancedtumorcontrol pages 1-4).

12.4 Clinical trials and trial infrastructure

INTUITT-NF2 (NCT04374305): a randomized, open-label, phase II platform-basket master study testing multiple sub-studies (e.g., brigatinib; neratinib; retifanlimab + bevacizumab) with radiographic response rate by tumor type used for interim activity decisions; long-term observation up to 10 years (ClinicalTrials.gov; posted 2020; recruiting per retrieved metadata) (NCT04374305 chunk 1, NCT04374305 chunk 3).
Everolimus pre-surgical PK/PD (NCT01880749): early-phase study giving everolimus 10 mg daily for 10 days preoperatively and assessing phospho-S6 inhibition in tumor tissue (ClinicalTrials.gov; 2013) (NCT01880749 chunk 1).
Lapatinib concentration/activity (NCT00863122): endpoints include phospho-ErbB2 in tumor tissue at surgery and tumor markers after lapatinib exposure; includes NF2 mutation analysis and tissue drug concentration comparisons (ClinicalTrials.gov; 2009) (NCT00863122 chunk 2).

12.5 MAXO term suggestions (treatment actions)

Surgical excision of schwannoma: MAXO:0000004 Surgical procedure (general)
Stereotactic radiosurgery: MAXO:0000008 Radiotherapy (general)
Anti-VEGF therapy (bevacizumab): MAXO:0000753 Monoclonal antibody therapy (general)
Molecular targeted therapy trials (e.g., TEAD inhibitors, kinase inhibitors): MAXO:0000058 Targeted therapy (general)

13. Prevention

13.1 Primary prevention

No primary prevention strategies for sporadic schwannoma were identified in the retrieved evidence set.

13.2 Secondary prevention / surveillance

Perrino et al. (Clinical Cancer Research, Feb 2025) is explicitly focused on surveillance recommendations in pediatric NF2-, SMARCB1-, and LZTR1-related schwannomatosis, reflecting the shift toward structured screening/surveillance in gene-defined predisposition syndromes (perrino2025updateoncancer pages 3-4).

14. Other Species / Natural Disease

Not addressed in the retrieved evidence set.

15. Model Organisms

Mouse models and primary human tumor cell systems were used to establish the preclinical efficacy of TEAD palmitoylation inhibitors and genetic YAP/TAZ ablation in NF2-null schwannoma (laraba2023inhibitionofyaptazdriven pages 1-2).
Immune-competent syngeneic VS models were used to test anti-PD1 + anti-VEGF combination strategies with hearing preservation endpoints (lu2024enhancedtumorcontrol pages 1-4).

Expert synthesis and analysis (2023–2025 emphasis)

Nosology and genetics have converged: a key recent development is the 2022 international consensus repositioning schwannomatosis as an umbrella term and renaming “neurofibromatosis type 2” to NF2-related schwannomatosis, with diagnosis increasingly driven by molecular evidence and explicit handling of mosaicism (tamura2024historicaldevelopmentof pages 1-3, tamura2024historicaldevelopmentof pages 3-4, perrino2025updateoncancer pages 3-4).
Bevacizumab remains the most evidence-supported systemic therapy for NF2-related progressive VS, with consistent hearing preservation/tumor control signals across systematic reviews and real-world cohorts—tempered by hypertension and discontinuation rates and common post-discontinuation progression/relapse (chiranth2023asystematicreview pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, douwes2024bevacizumabtreatmentfor pages 9-11).
Mechanism-driven therapeutic opportunities are expanding: the Hippo–YAP/TAZ–TEAD axis has moved from correlative pathway dysregulation to direct, regressive preclinical intervention (TEAD palmitoylation inhibitors) in 2023 (laraba2023inhibitionofyaptazdriven pages 1-2, laraba2023inhibitionofyaptazdriven media d8f8c3e0). Platform trials such as INTUITT-NF2 represent a pragmatic clinical strategy to screen multiple targeted agents efficiently in rare NF2-related tumors (NCT04374305 chunk 1).

Key limitations of this report (due to retrieval constraints)

ICD-10/ICD-11, MeSH, Orphanet, OMIM IDs for schwannoma/VS were not retrieved in the current tool context.
Environmental/lifestyle risk factors, protective factors, and gene–environment interactions were not supported by evidence in the retrieved excerpts.
Broad epidemiology for all schwannomas (beyond NF2-related statistics) and detailed histopathology/IHC differentials were not extractable from the current corpus.

References

(otaner2026vestibularschwannomagenetic pages 1-2): Franciska Otaner, Vratko Himic, Luis O. Vargas, Matthew Abikenari, Neelesh Pandey, Shayndhan Sivanathan, Olivia Kalmanson, Aparna Govindan, Diane Jung, Dagoberto Estevez-Ordonez, Amy Wang, Sanjeeva Jeyaretna, Ashish H. Shah, Ricardo J. Komotar, Bradley Gampel, Christine Dinh, and Michael E. Ivan. Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies. Journal of Neuro-Oncology, May 2026. URL: https://doi.org/10.1007/s11060-026-05621-4, doi:10.1007/s11060-026-05621-4. This article has 0 citations and is from a peer-reviewed journal.
(screnci2024bevacizumabforvestibular pages 1-2): Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, and Guillaume Coll. Bevacizumab for vestibular schwannomas in neurofibromatosis type 2: a systematic review of tumor control and hearing preservation. Journal of Clinical Medicine, 13:7488, Dec 2024. URL: https://doi.org/10.3390/jcm13237488, doi:10.3390/jcm13237488. This article has 7 citations.
(OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis): Open Targets Query (schwannoma,vestibular schwannoma,schwannomatosis, 7 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(perrino2025updateoncancer pages 3-4): Melissa R. Perrino, Marjolijn C. J. Jongmans, Gail E. Tomlinson, Mary-Louise C. Greer, Sarah R. Scollon, Sarah G. Mitchell, Jordan R. Hansford, Kris Ann P. Schultz, Wendy K. Kohlmann, Jennifer M. Kalish, Suzanne P. MacFarland, Anirban Das, Kara N. Maxwell, Stefan M. Pfister, Rosanna Weksberg, Orli Michaeli, Uri Tabori, Gina M. Ney, Philip J. Lupo, Jack J. Brzezinski, Douglas R. Stewart, Emma R. Woodward, and Christian P. Kratz. Update on cancer and central nervous system tumor surveillance in pediatric nf2-, smarcb1-, and lztr1-related schwannomatosis. Clinical cancer research : an official journal of the American Association for Cancer Research, Feb 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3278, doi:10.1158/1078-0432.ccr-24-3278. This article has 8 citations.
(rai2025classificationofschwannomas pages 1-2): Pranjal Rai, Girish Bathla, Neetu Soni, Amit Desai, Dinesh Rao, Prasanna Vibhute, and Amit Agarwal. Classification of schwannomas and the new naming convention for "neurofibromatosis-2": genetic updates and international consensus recommendation. The neuroradiology journal, pages 19714009251313510, Jan 2025. URL: https://doi.org/10.1177/19714009251313510, doi:10.1177/19714009251313510. This article has 7 citations and is from a peer-reviewed journal.
(tamura2024historicaldevelopmentof pages 1-3): Ryota TAMURA, Masahiro YO, and Masahiro TODA. Historical development of diagnostic criteria for nf2-related schwannomatosis. Neurologia medico-chirurgica, 64:299-308, Aug 2024. URL: https://doi.org/10.2176/jns-nmc.2024-0067, doi:10.2176/jns-nmc.2024-0067. This article has 12 citations and is from a peer-reviewed journal.
(chiranth2023asystematicreview pages 1-2): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 27 citations and is from a peer-reviewed journal.
(douwes2024bevacizumabtreatmentfor pages 9-11): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.
(NCT04374305 chunk 1): Scott R. Plotkin, MD, PhD. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2). Scott R. Plotkin, MD, PhD. 2020. ClinicalTrials.gov Identifier: NCT04374305
(tamura2024historicaldevelopmentof pages 3-4): Ryota TAMURA, Masahiro YO, and Masahiro TODA. Historical development of diagnostic criteria for nf2-related schwannomatosis. Neurologia medico-chirurgica, 64:299-308, Aug 2024. URL: https://doi.org/10.2176/jns-nmc.2024-0067, doi:10.2176/jns-nmc.2024-0067. This article has 12 citations and is from a peer-reviewed journal.
(lu2024enhancedtumorcontrol pages 1-4): Simeng Lu, Zhenzhen Yin, Limeng Wu, Yao Sun, Jie Chen, Lai Man Natalie Wu, Janet L. Oblinger, Day Caven Blake, Lukas D. Landegger, Richard Seist, William Ho, Bingyu Xiu, Adam P. Jones, Alona Muzikansky, Konstantina M. Stankovic, Scott R. Plotkin, Long-Sheng Chang, and Lei Xu. Enhanced tumor control and hearing loss prevention achieved with combined immune checkpoint inhibitor and anti-vegf therapy in vestibular schwannoma model. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.29.630658, doi:10.1101/2024.12.29.630658. This article has 3 citations.
(perrino2025updateoncancer pages 5-7): Melissa R. Perrino, Marjolijn C. J. Jongmans, Gail E. Tomlinson, Mary-Louise C. Greer, Sarah R. Scollon, Sarah G. Mitchell, Jordan R. Hansford, Kris Ann P. Schultz, Wendy K. Kohlmann, Jennifer M. Kalish, Suzanne P. MacFarland, Anirban Das, Kara N. Maxwell, Stefan M. Pfister, Rosanna Weksberg, Orli Michaeli, Uri Tabori, Gina M. Ney, Philip J. Lupo, Jack J. Brzezinski, Douglas R. Stewart, Emma R. Woodward, and Christian P. Kratz. Update on cancer and central nervous system tumor surveillance in pediatric nf2-, smarcb1-, and lztr1-related schwannomatosis. Clinical cancer research : an official journal of the American Association for Cancer Research, Feb 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3278, doi:10.1158/1078-0432.ccr-24-3278. This article has 8 citations.
(xu2024nf2anunderestimated pages 2-3): Duo Xu, Shiyuan Yin, and Yongqian Shu. Nf2: an underestimated player in cancer metabolic reprogramming and tumor immunity. NPJ Precision Oncology, Jun 2024. URL: https://doi.org/10.1038/s41698-024-00627-5, doi:10.1038/s41698-024-00627-5. This article has 34 citations and is from a peer-reviewed journal.
(laraba2023inhibitionofyaptazdriven pages 1-2): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 64 citations and is from a highest quality peer-reviewed journal.
(laraba2023inhibitionofyaptazdriven pages 2-3): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 64 citations and is from a highest quality peer-reviewed journal.
(laraba2023inhibitionofyaptazdriven media d8f8c3e0): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 64 citations and is from a highest quality peer-reviewed journal.
(douwes2024bevacizumabtreatmentfor pages 2-4): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.
(douwes2024bevacizumabtreatmentfor pages 8-9): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.
(douwes2024bevacizumabtreatmentfor pages 5-8): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.
(douwes2024bevacizumabtreatmentfor pages 4-5): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.
(NCT04374305 chunk 3): Scott R. Plotkin, MD, PhD. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2). Scott R. Plotkin, MD, PhD. 2020. ClinicalTrials.gov Identifier: NCT04374305
(NCT01880749 chunk 1): Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas. NYU Langone Health. 2013. ClinicalTrials.gov Identifier: NCT01880749
(NCT00863122 chunk 2): Concentration and Activity of Lapatinib in Vestibular Schwannomas. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 2009. ClinicalTrials.gov Identifier: NCT00863122

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Subtypes

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Definition and overview

1.2 Key identifiers and ontology mappings (available in current corpus)

1.3 Common synonyms / alternative names

1.4 Evidence-source type

2. Etiology

2.1 Primary causal factors

2.1.1 Sporadic schwannoma / VS

2.1.2 Schwannomatosis syndromes (germline predisposition)

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

3. Phenotypes (clinical features)

3.1 Core phenotype spectrum (with suggested HPO terms)

Vestibular schwannoma (sporadic or NF2-related)

Schwannomatosis syndromes (NF2-, SMARCB1-, LZTR1-related)

3.2 Age of onset / progression

3.3 Quality-of-life impact

4. Genetic/Molecular Information

4.1 Causal genes and molecular classification (2022 consensus framework)

4.2 Pathogenic variants / variant origin

4.3 Pathways and mechanisms (current understanding; 2023–2024 emphasis)

4.3.1 Hippo–YAP/TAZ–TEAD as a therapeutic vulnerability (primary evidence)

4.4 Epigenetic / multi-omics profiling

Suggested GO / CL terms (for knowledge-base annotation)

5. Environmental Information

6. Mechanism / Pathophysiology (causal chain)

6.1 Example causal chain: NF2 loss → pathway dysregulation → tumor growth and hearing loss

6.2 Hearing loss mechanisms in VS

7. Anatomical Structures Affected

7.1 Organ and system level (with UBERON suggestions)

7.2 Tissue/cell level

7.3 Subcellular level

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology statistics (from retrieved sources)

10. Diagnostics

10.1 2022 international diagnostic criteria highlights (NF2-related schwannomatosis)

10.2 Diagnostic testing modalities (from available evidence)

10.3 Differential diagnosis

11. Outcome / Prognosis

11.1 Treatment response metrics as prognostic indicators

11.2 Progression after stopping therapy

12. Treatment (current applications and real-world implementations)

12.1 Standard local management

12.2 Systemic therapies (NF2-related VS): bevacizumab and beyond

12.3 Emerging targeted and immunologic strategies (2023–2024)

12.4 Clinical trials and trial infrastructure

12.5 MAXO term suggestions (treatment actions)

13. Prevention

13.1 Primary prevention

13.2 Secondary prevention / surveillance

14. Other Species / Natural Disease

15. Model Organisms

Expert synthesis and analysis (2023–2025 emphasis)

Key limitations of this report (due to retrieval constraints)

Artifacts